Results 201 to 210 of about 4,346,835 (341)

Optimizing Electrodiagnostic Studies: The Role of Clinical History in Improving Diagnostic Concordance-A Retrospective Study. [PDF]

Diagnostics (Basel)
López-López CO, Touron De Alba M, Montes-Castillo ML, Vázquez-Mellado J.   +3 more
europepmc   +1 more source

Validation of a newly developed questionnaire regarding clinical history in patients with breast and colorectal cancers. [PDF]

ARYA Atheroscler, 2021
Vafaei Z, Najafian J, Shekarchizadeh M, Mostafavi S, Darakhshandeh A, Khosravifarsani M, Ashrafi F, Sharifi M, Mohammadifard N, Emami MH, Haghjooy-Javanmard S, Sarrafzadegan N.   +11 more
europepmc   +1 more source

13. Developing a Brief Clinical Pathway for Trauma-Focused Management of Individuals With Trauma Histories Admitted to the Medical Hospital

Sophia Buzanis, Karen Jakubowski, Caroline Christian, Julianne Griffith, Meghan Pale, Priya Gopalan, Meredith Spada   +6 more
openalex   +1 more source

Natural History of Nipah Virus in Hamsters: Strain, Route, and Sex-Associated Variability Characterized Using Large Datasets to Inform Pre-Clinical Study Design [PDF]

Katherine Davies, Stephen R. Welch, JoAnn D. Coleman-McCray, Teresa E. Sorvillo, Virginia Aida-Ficken, Christina F. Spiropoulou, Jessica R. Spengler   +6 more
openalex   +1 more source

Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. 1964 [PDF]

, 1993
Leopold G. Koss, N. G. Voutsa, H. Grabstald   +2 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Considering clinical history as a determinant of human neuron function. [PDF]

Brain Commun
Booker SA.
europepmc   +1 more source

Clinical, histological and genetic findings in a donor with a clinical history of type 1 Autoimmune Polyendocrinopathy Syndrome. [PDF]

Am J Ophthalmol Case Rep, 2022
Culp CJ, Pappas CM, Toso M, Qu P, Mamalis N, Hageman GS.   +5 more
europepmc   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

A case of a (not so) diffuse leptomeningeal glioneuronal tumor with an unusual clinical history. [PDF]

J Neuropathol Exp Neurol
Faraj CA, McCutcheon IE, Schomer DF, Aldape K, Quezado M, Abdullaev Z, Gubbiotti MA.   +6 more
europepmc   +1 more source